Cite
HARVARD Citation
Bergeat, D. et al. (n.d.). LOXL2 is a prognosis biomarker and a potential therapeutic target in intrahepatic cholangiocarcinoma. HPB. pp. e863-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Bergeat, D. et al. (n.d.). LOXL2 is a prognosis biomarker and a potential therapeutic target in intrahepatic cholangiocarcinoma. HPB. pp. e863-. [Online].